Nebula Research & Development LLC Raises Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Nebula Research & Development LLC raised its position in Cryoport, Inc. (NASDAQ:CYRX) by 21.6% during the fourth quarter, HoldingsChannel reports. The firm owned 12,442 shares of the company’s stock after purchasing an additional 2,207 shares during the period. Nebula Research & Development LLC’s holdings in Cryoport were worth $97,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CYRX. Avanza Fonder AB acquired a new position in Cryoport during the fourth quarter worth about $64,000. Russell Investments Group Ltd. boosted its holdings in shares of Cryoport by 135.5% during the 4th quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company’s stock worth $100,000 after purchasing an additional 7,407 shares during the last quarter. Olympiad Research LP purchased a new stake in shares of Cryoport in the fourth quarter valued at approximately $103,000. Fox Run Management L.L.C. acquired a new stake in shares of Cryoport in the fourth quarter valued at approximately $111,000. Finally, Canada Pension Plan Investment Board purchased a new position in Cryoport during the fourth quarter worth approximately $117,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Price Performance

Shares of CYRX opened at $5.86 on Friday. The firm has a 50-day simple moving average of $5.80 and a two-hundred day simple moving average of $6.90. The stock has a market cap of $293.80 million, a PE ratio of -1.73 and a beta of 1.92. Cryoport, Inc. has a 1-year low of $4.58 and a 1-year high of $17.41. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Cryoport (NASDAQ:CYRX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same quarter last year, the business posted ($0.29) EPS. As a group, analysts forecast that Cryoport, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on CYRX. Guggenheim restated a “buy” rating and issued a $10.00 target price on shares of Cryoport in a report on Wednesday, April 16th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Cryoport in a research report on Wednesday, April 16th. UBS Group boosted their target price on shares of Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Finally, Roth Mkm restated a “buy” rating and set a $15.00 price target on shares of Cryoport in a report on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.67.

Insider Activity at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. This represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 19,830 shares of company stock worth $118,353. 10.10% of the stock is currently owned by company insiders.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.